Bcl-2 expression correlates with lymphovascular invasion and long-term prognosis in breast cancer

Alterations in the mechanisms of apoptosis are responsible not only for the progression of breast cancer, but for different responses to treatment as well. Among the genes regulators of apoptosis, the tumor suppressor gene p53 and the bcl-2 gene have raised interest for their possible role as predic...

Full description

Saved in:
Bibliographic Details
Published inBreast cancer research and treatment Vol. 99; no. 1; pp. 77 - 83
Main Authors NERI, Alessandro, MARRELLI, Daniele, PINTO, Enrico, ROVIELLO, Franco, DEMARCO, Giovanni, MARIANI, Federico, DESTEFANO, Alfonso, MEGHA, Tiziana, CARUSO, Stefano, CORSO, Gianni, CIOPPA, Tommaso
Format Journal Article
LanguageEnglish
Published Dordrecht Springer 01.09.2006
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Alterations in the mechanisms of apoptosis are responsible not only for the progression of breast cancer, but for different responses to treatment as well. Among the genes regulators of apoptosis, the tumor suppressor gene p53 and the bcl-2 gene have raised interest for their possible role as predictors of response to therapy and markers of prognosis. The purpose of our study was to prospectively analyze the prognostic value of the expression of p53 and bcl-2 genes in a series of 235 consecutive patients operated on for breast cancer at the Department of General Surgery and Surgical Oncology of the University of Siena, Italy.p53 and bcl-2 expression were evaluated by immunohistochemistry, their association with conventional clinicopathological factors was analyzed by univariate analysis and their prognostic impact was evaluated by multivariate analysis.p53 and bcl-2 were detected respectively in 15.7 and 75.7% of cases, and resulted significantly related to presence of estrogen receptors for p53 over-expression and presence of peritumor lymphovascular invasion (LVI) for bcl-2 expression. With a median follow-up of 79 months, an independent negative prognostic impact on disease free and overall survival was observed for presence of LVI, absence of bcl-2 expression and number of involved axillary lymphnodes. The expression of bcl-2 improved the prognosis of LVI positive tumors up to values similar to LVI negative cases, while its absence associated to presence of LVI resulted in a poor outcome with only 28% of patients alive at 8 years. These data may indicate that expression of bcl-2 is a marker of breast cancers with reduced capability of distant colonization, even in presence of LVI, and may be particularly useful in the clinical setting, allowing to identify a subset of patients with an high risk of relapse.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0167-6806
1573-7217
DOI:10.1007/s10549-006-9183-2